Patient Guide: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 15 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06892522
Status: 🟢 Enrolling Now
Condition: Multiple Myeloma
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 15 locations across the country.

Top locations include:
  • • Denver, Colorado
  • • Chapel Hill, North Carolina
  • • Coffs Harbour, New South Wales
  • • And 12 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib - Join Clinical Trial NCTNCT06892522

How to Join This Clinical Trial - NCTNCT06892522

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Multiple Myeloma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06892522 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 15 locations. Find a study site near you:

Clinical Research Site

Denver, Colorado 80218 - United States

Status: RECRUITING

Clinical Research Site

Chapel Hill, North Carolina 27514 - United States

Status: RECRUITING

Clinical Research Site

Coffs Harbour, New South Wales 2450 - Australia

Status: RECRUITING

Clinical Research Site

Port Macquarie, New South Wales 2444 - Australia

Status: RECRUITING

Clinical Research Site

Westmead, New South Wales 2145 - Australia

Status: RECRUITING

Clinical Research Site

South Brisbane, Queensland 4101 - Australia

Status: RECRUITING

Clinical Research Site

Adelaide, South Australia 5000 - Australia

Status: RECRUITING

Clinical Research Site

Melbourne, Victoria 3000 - Australia

Status: RECRUITING

Clinical Research Site

West Perth, Western Australia 6005 - Australia

Status: RECRUITING

Clinical Research Site

Ramat Gan, Tel Aviv 5265601 - Israel

Status: RECRUITING

And 5 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships